Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study to Evaluate the Efficacy and Safety of Baricitinib for Reduction of HIV in the Central Nervous System

NCT05452564 is registered in ClinicalTrials.gov with William Tyor as lead sponsor.

NCT NCT05452564
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05452564 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study to Evaluate the Efficacy and Safety of Baricitinib for Reduction of HIV in the Central Nervous System
Lead sponsor
William Tyor
Phase
Phase 2
Overall status
Recruiting
Start date
May 18, 2023
Completion date
January 31, 2028
Enrollment
95 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

human immunodeficiency virus